Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.

By L. Saiman, B. Marshall, N. Mayer-Hamblett, J. Burns, A. Quittner, Debra A Cibene, Sarah J Coquillette, Ann Yunker Fieberg, F. Accurso, P. Campbell. Journal of the American Medical Association (JAMA), 2003

994 citations recorded by the source corpus.

Subfields: Epidemiology, Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/be58b2a159ec96642baf422f23e5801008ed78e1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. T. Bjarnsholt
2. Niels Høiby
3. M. Givskov
4. Søren Molin
5. O. Ciofu
6. S. Kanoh
7. B. Rubin
8. C. Beloin

In Pulmonary and Respiratory Medicine

1. T. Bjarnsholt

Citations in the corpus

• British Thoracic Society guideline for non-CFbronchiectasis (2010, background): “Controlled clinical trials are lacking in bronchiectasis. Evidence is available for the long-term use of azithromycin in patients with CF-derived bronchiectasis”
• Mechanisms of Action and Clinical Application of Macrolides as Immunomodulatory Medications (2010, background): “A larger, multicenter study also demonstrated significant lung function improvements and fewer intravenous antibiotic courses for subjects with CF who were on azithromycin (243).”
• Genome-wide identification of novel small RNAs in Pseudomonas aeruginosa (2013, background): “After the introduction of strand-specific RNA-seq protocols the number of asRNAs detected has increased exponentially, with tens to hundreds of asRNAs detected in every bacterium studied (15,24-30).”
• Azithromycin: mechanisms of action and their relevance for clinical applications. (2014, background): “Drawing on this experience in DPB, long-term, low-dose azithromycin therapy was subsequently introduced in CF (Saiman et al., 2003), non-CF bronchiectasis (Anwar et al.”
• European Position Paper on Rhinosinusitis and Nasal Polyps 2020. (2020, background): “A systematic review was performed by Wilson in 2014((24)).”
• Biofilm-Related Infections: Bridging the Gap between Clinical Management and Fundamental Aspects of Recalcitrance toward Antibiotics (2014, background): “aeruginosa demonstrated an improvement in respiratory function and a reduced number of exacerbations compared with the placebo (301).”
• Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. (2007, positive): “These trials were longer term, lasting from 3 (68) to 6 (67, 69) months of treatment, and involving between 41 (69) and 185 (67) patients with CF.”
• Antibiotic resistance of bacterial biofilms. (2010, background): “both CF children and adults have shown significant improvement of their lung 305 function (92) (93) (94).”
• A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation (2011, methodology): “Weight gain was measured in two studies of oral azithromycin.(22,23) In those trials, the mean treatment effect with azithromycin as compared with placebo during the 24-week treatment period was a weight gain of 0.”